Redding, California, Oct. 21, 2021 (GLOBE NEWSWIRE) -- According to a new market research report "Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin], Application (Immunology, Hematology, Neurology), and End User (Hospital, Clinical Research Lab, Academic Institutes) - Forecast to 2027", published by Meticulous Research®, the plasma fractionation market is expected to grow at a CAGR of 7% from 2020 to reach $41.4 billion by 2027.
Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5117
Plasma fractionation is a process of separation, extraction, and purification of specific components from the plasma. Recently, the growing number of chronic cases with aged people has increased the demand for plasma-derived products. In the case of aged people, but in inborn, immunological disorders have increased over the past few years. For instance, the number of genes identified with inborn errors of immunity was 269 in 2015, which increased to 430 in 2019. Thus, the demand for plasma-derived immunoglobulins and other products is rising at a rapid pace.
COVID-19 Impact on the Plasma Fractionation Market
The outbreak of COVID-19 forced countries to undertake initiatives to adopt plasma therapy. For instance, the European Commission, DG DIGIT, developed and hosted a database in compliance with Data Protection Regulations 2016/679 and 2018/17/25 to support the monitoring of convalescent plasma donation and use monitoring. The database was designed in collaboration with the European Blood Alliance (EBA). The EBA was responsible for coordinating the data entry by all blood establishments across the EU.
Apart from government initiatives, companies are also developing an effective treatment against COVID-19. For instance, Octapharma AG (Switzerland) launched a special project team to explore new therapies for COVID-19. The company also announced that it had joined other plasma fractionation leaders to develop a potential plasma-derived hyperimmune immunoglobulin therapy for treating COVID-19. In February 2020, Grifols, S.A. (Spain) agreed with the Public Investment Fund of Saudi Arabia (PIF) to build a network of plasma collection centers and other facilities for producing plasma medicines, including a plasma fractionation plant a purification plant in Saudi Arabia.
Thus, plasma-derived immunoglobulin played an important role in the treatment of the disease, thus created a positive impact on the growth of the plasma fractionation market.
Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5117
The plasma fractionation market is segmented on the basis of product [Immunoglobulins (IVIG, SCIG, and others), coagulation factors, albumin, protease inhibitors, and others), application (immunology, hematology, neurology, critical care, hemato-oncology, rheumatology, and others), end user (hospitals & clinics, clinical research laboratories, and academic institutes), and geography. The study also evaluates industry competitors and analyzes the market at regional and country levels.
Based on product type, the immunoglobulins accounted for the largest share of the overall plasma fractionation market in 2020. Immunoglobulins are used as first-line therapy for various neurologic, immunologic, and hematologic conditions. The most common use of immunoglobulin therapy is to treat primary immune deficiencies and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Intravenous immunoglobulin (IVIg) is also being considered for various neurological diseases, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome. The large share of this segment is attributed to the rising adoption of SCIg and the increasing on- and off-label use of immunoglobulins for various indications.
Based on application, the neurology segment commanded the largest share of the overall plasma fractionation market in 2020. The rising number of neurological disorders and the focus of vendors on discovering plasma products for neurology.
Based on end user, the hospitals and clinics segment is estimated to command the largest share of the overall plasma fractionation market in 2020. The growing need for therapies for immunodeficiency disorders, growing number of hospitals & healthcare expenditure, and rising consumption of plasma-derived products by hospitals & clinics are some of the major factors driving the growth of this segment.
Quick Buy – Plasma Fractionation Research Report: https://www.meticulousresearch.com/Checkout/17799149
Based on geography, in 2020, the North America accounted for the largest share of the global plasma fractionation market. On the other hand, Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period. The factors driving the growth of the APAC plasma fractionation market are rising consumption of plasma-derived products, presence of leading players, contract fractionation agreements between countries, and programs for increasing the use of plasma and fractionation.
The report also includes an extensive assessment of the product portfolio, geographic analysis, and key strategic developments adopted by leading market participants in the industry over the past four years. The plasma fractionation market witnessed several new product launches, approvals, agreements, partnerships & collaborations, expansions, and acquisitions in recent years. For instance, in April 2020, Grifols, S.A. (Spain) launched HyperRAB (3-mL – 900-IU). It will be used for treatment for rabies post-exposure prophylaxis.
Some of the key players operating in the global plasma fractionation market are CSL Limited (Australia), Grifols, S.A. (Spain), Octopharma AG (Switzerland), Kedrion S.P.A. (Italy), Shire plc (U.K.), Biotest AG (Germany), China Biologic Products Holdings, Inc. (China), Bio Products Laboratory Ltd (U.K.), Japan Blood Products Organization (Japan), SeraCare Life Sciences, Inc. (U.S.), Haemonetics Corporation (U.S.),BioIVT LLC (U.S.), Green Cross Biotherapeutics Inc. (Canada), Sartorius Stedim Biotech GmbH (Germany), LFB S.A. (France), Scinomed Ltd. (U.K.), Oxbridge Pharma Ltd (U.K.), Sanquin (Netherlands), Shanghai Institute of Biological Products Co., Ltd. (China), Hualan Biological Engineering Inc (China), Walvax Biotechnology Co., Ltd. (China), Shanxi Kangbao Biological Product Co. Ltd. (China), Sichuan YuandaShuyang Pharmaceutical Co., Ltd. (China), Reliance Life Sciences (India), IntasBiopharm Pharmaceuticals Ltd. (India), Hemarus (India), Japan Blood Products Organization (Japan), Chemo-Sero Therapeutic Research Institute (Japan), SK Plasma Co., Ltd. (Korea), Korean Red Cross (Korea), STROVI (Malaysia), The National Bioproducts Institute (South Africa), Kamada Ltd. (Israel), MDA Plasma Fractionation Center (Israel), and Hemobras (Brazil) among others.
To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/plasma-fractionation-market-5117
Scope of the Report:
Plasma Fractionation Market, by Product
- Immunoglobulins
- Intravenous Immunoglobulins
- Subcutaneous Immunoglobulins
- Others
- Coagulation Factors
- Albumin
- Protease Inhibitors
- Others
Plasma Fractionation Market, by Application
- Immunology
- Hematology
- Neurology
- Critical Care
- Hemato-Oncology
- Rheumatology
- Others
Plasma Fractionation Market, by End User
- Hospitals& Clinics
- Clinical Research Laboratories
- Academic Institutes
Plasma Fractionation Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5117
Amidst this crisis, Meticulous Research® is continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here- https://www.meticulousresearch.com/custom-research
Related Reports:
Blood Screening Market by Product (Reagents & Kits, Instruments, Software), Technology (NAAT [Real-time PCR], ELISA [CLIA, FIA, CI], Rapid Tests, Western Blotting, NGS), and End User (Blood Banks, Hospitals, Laboratories) - Global Forecast to 2027
https://www.meticulousresearch.com/product/blood-screening-market-5164
Vaccines Market by Indication (Influenza, Rotavirus, DTP, COVID-19), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccines, Live Attenuated Vaccines), and Valence (Multivalent, Monovalent Vaccines) - Forecast to 2028
https://www.meticulousresearch.com/product/vaccines-market-5076
Research Antibodies and Reagents Market by Product {Antibodies [Type (Primary, Secondary), Production, Source, Research Area (Oncology, Neurology)], Reagents}, Technology (ELISA, Western Blot), Application, End User (Pharma, Academia) - Global Forecast to 2027
https://www.meticulousresearch.com/product/research-antibodies-reagents-market-5055
Plasmapheresis Market Size by Product Type (Instruments and Disposables), by Technology (Centrifugation and Membrane Filtration), Application (Therapeutic Plasmapheresis and Source Plasma Collection), End User (Biopharmaceutical Companies, Hospitals and Clinics, Others) - Global Forecasts to 2022
https://www.meticulousresearch.com/product/plasmapheresis-market-3092
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since its inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Content Source: https://www.meticulousresearch.com/pressrelease/366/plasma-fractionation-market-2027
Mr. Khushal Bombe Meticulous Research® Direct Lines: +1-646-781-8004 (North America) +44-203-868-8738 (Europe) +91 744-7780008 (Asia-Pacific) Email- sales@meticulousresearch.com Visit Our Website: https://www.meticulousresearch.com/ Meticulous Research® Blog: https://meticulousblog.org/ Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
